Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACcomplisH phase 2 trial of weekly TransCon CNP in prepubertal children with achondroplasia
2019-002754-22Phase 2Completed
- Sponsor
- Ascendis Pharma
- Start
- Sep 2019
- Modality
- Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of navepegritide in achondroplasia (ACH) (3 arms), sponsored by Ascendis Pharma. Primary endpoint: Safety endpoints. Started Sep 2019; status: completed.
02
Drugs
navepegritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on 2019-002754-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002754-22.